| Ytd | -7.56% | |
| 1y | 141.29% |
| Open | 79.00 | Prev Close | 80.00 | Low | 76.60 | High | 79.78 | Mkt Cap | 3.52B |
| Vol | 91.18K | Avg Vol | 703.60K | EPS | -9.69 | P/E | N/A | Forward P/E | -8.11 |
| Beta | 3.24 | Short Ratio | 12.78 | Inst. Own | 86.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 70.82 | 200-d Avg | 73.26 | 1yr Est | 72.38 |
GRAL News
GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer ear
Bank of America Corp DE raised its holdings in shares of GRAIL, Inc. (NASDAQ: GRAL) by 29.0% during
GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based
GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. F
The FDA's advisory committee will meet on September 23 to review the PMA application for GRAIL&#
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Gall
Grail said on Friday the U.S. FDA plans to hold a meeting of outside experts to review its multi-c
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can
MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company wh
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
GRAIL NASDAQ: GRAL reported second-quarter revenue growth driven by higher Galleri test volumes, whi
GRAIL (NASDAQ:GRAL) reported quarterly losses of $(2.56) per share which beat the analyst consensus
Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has
NEW YORK--(BUSINESS WIRE)---- $GRAL #ClassAction--Faruqi & Faruqi, LLP, a leading national securitie
New York, New York--(Newsfile Corp. - August 4, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nati
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholder
LOS ANGELES, Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Grail, Inc., (“Grail” or
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Ac
SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GRAI
SAN FRANCISCO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogni
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can
Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price t
Goldman Sachs analyst Evie Koslosky initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral rati
TD Cowen analyst Dan Brennan maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target
Piper Sandler analyst David Westenberg maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises th
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can
Wall Street analysts changed outlook on top stocks. See rating changes on NKE, SMPL, WSR, NTNX, and
Top Wall Street analysts changed outlook on top names. Initiations & upgrades noted. For full ch
Mizuho analyst Bradley Bowers initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral rating and
Piper Sandler analyst David Westenberg initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral r
GRAIL stock rises after Epic partnership expands Galleri test access; trial shows Stage IV reduction
Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within T
Guggenheim analyst Subbu Nambi maintains GRAIL (NASDAQ:GRAL) with a Buy and lowers the price targ
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can
Morgan Stanley analyst Tejas Savant maintains GRAIL (NASDAQ:GRAL) with a Equal-Weight and lowers
GRAIL stock tumbles after NHS-Galleri trial misses main goal, despite a drop in late-stage cancer ca
Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:GRAL) with a Buy and lowers the pri
Baird analyst Catherine Schulte maintains GRAIL (NASDAQ:GRAL) with a Outperform and lowers the pr
The Supreme Court struck down President Donald Trump's global tariffs, ruling IEEPA does not aut
(Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were up
